Viridian data lift prospects for thyroid eye disease drug

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

By Delilah Alvarado • May 5, 2026

Vertex earnings get muted investor response

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

By Jacob Bell • May 5, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Cytokinetics heart drug scores in closely watched trial

Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.

By Ben Fidler • May 5, 2026

Cytospire hauls in $83M for a new type of T cell engager

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies. 

By Gwendolyn Wu • May 5, 2026

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

By Delilah Alvarado • May 4, 2026

With $97M, Latus pursues a different kind of Huntington’s gene therapy

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

By Ben Fidler • May 4, 2026

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

By Ben Fidler • May 4, 2026

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.

By Gwendolyn Wu • May 1, 2026

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

By Ben Fidler • May 1, 2026

Moderna sees revenue bump from international COVID vaccine sales

The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.

By Delilah Alvarado • May 1, 2026

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

By Jacob Bell , Jonathan Gardner • May 1, 2026

Two biotechs raise a combined $556M in latest spurt of IPOs

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.

By Gwendolyn Wu • April 30, 2026

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

By Jonathan Gardner • April 30, 2026

UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

By Delilah Alvarado • April 30, 2026

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

By Gwendolyn Wu • April 29, 2026

Teva nabs experimental Tourette drug in $700M Emalex buyout

A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business. 

By Jacob Bell • April 29, 2026

Chiesi to buy KalVista in $1.9B deal for rare disease drug

The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.

By Kristin Jensen • April 29, 2026

FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech

Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multiple myeloma drug.

By BioPharma Dive staff • April 29, 2026

FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results

Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.

By Ben Fidler • April 28, 2026

Coultreon banks $125M to support testing of former Galapagos immune drug

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases. 

By Delilah Alvarado • April 28, 2026

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.

By Gwendolyn Wu • April 28, 2026

Oruka surges as long-acting psoriasis drug shows early promise

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently. 

By Delilah Alvarado • April 27, 2026

Veradermics soars on positive data for baldness treatment

The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.  

By Jonathan Gardner • April 27, 2026

Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics

Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

By BioPharma Dive staff • Updated April 24, 2026

Revolution drug shows promise in early pancreatic cancer

The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.

By Jonathan Gardner • April 22, 2026